U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748156) titled 'SNC116 Therapy for Refractory Systemic Lupus Erythematosus' on July 26.
Brief Summary: This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
DRUG: SNC116
The formulation of SNC116 is an injection solution. The initial dose is 2E8 TU and it is administered via a single intravenous infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Information provided by (Responsib...